高 偉育

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Radiofrequency Ablation 60%
3. Hepacivirus 32%
4. velpatasvir 31%
5. Liver Neoplasms 28%
6. Radiofrequency Therapy 28%
7. Taiwan 25%
8. Sofosbuvir 25%
9. Liver Diseases 21%
10. Fatty Liver 21%
11. Non-alcoholic Fatty Liver Disease 21%
12. Chronic Hepatitis C 20%
13. Recurrence 19%
14. Survival 18%
15. Sustained Virologic Response 18%
16. Survival Rate 16%
17. Propensity Score 16%
18. Liver 16%
19. Elasticity Imaging Techniques 15%
20. Fibrosis 15%
21. Cohort Studies 14%
22. Bilirubin 14%
23. Hepatitis B 13%
24. Blood Platelets 13%
25. Ribavirin 13%
26. Proton Pump Inhibitors 13%
27. Liver Cirrhosis 12%
28. Alanine Transaminase 12%
29. Chronic Hepatitis B 12%
30. Hepatitis B virus 12%
31. Biliary Tract Neoplasms 12%
32. Multivariate Analysis 11%
33. Albumins 11%
34. Neoplasms 11%
35. Antiviral Agents 10%
36. Population 10%
37. Colorectal Neoplasms 10%
38. 2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole 10%
39. MK-5172 10%
40. Renal Dialysis 10%
41. Serum 9%
42. Syndecan-2 9%
43. Aspartate Aminotransferases 9%
44. Virus Diseases 9%
45. Deep Learning 9%
46. Pyogenic Liver Abscess 9%
47. VP-P protocol 8%
48. Interleukin-2 Receptor alpha Subunit 8%
49. Incidence 8%
50. Chronic Renal Insufficiency 8%